期刊
RHEUMATOLOGY
卷 55, 期 5, 页码 775-779出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kev346
关键词
lupus; biologics; review
类别
资金
- UCB celltech
- Roche/Chugai
- Pfizer
- Abbvie
- Merck
- Mennarini
- Eli-lilly
With the explosion in biologics use in rheumatology, newer and smarter ways of using these drugs in different diseases have been advocated. SLE has to date been at the back of the biologics algorithms. Recently, the US Food and Drug Administration and European Medicines Evaluation Agency licensed belimumab for use in SLE, the first drug in > 30 years. A clinical review of the evidence that underlies the use of belimumab and other biologics in SLE reveals possible reasons why the results are not as spectacular as they are in other diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据